-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Biogen, Raises Price Target to $272

Benzinga·10/29/2026 19:20:37
Listen to the news
RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $256 to $272.